Raymond James Believes NGM Biopharmaceuticals (NGM) Won’t Stop Here


NGM Biopharmaceuticals (NGM) received a Buy rating from Raymond James analyst Steven Seedhouse yesterday. The company’s shares closed last Wednesday at $24.45, close to its 52-week high of $25.09.

According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 19.5% and a 58.0% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.

NGM Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.50, implying a 35.3% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.09 and a one-year low of $9.25. Currently, NGM Biopharmaceuticals has an average volume of 145.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts